Sugi Predict

Sugi Predict / Targets / PRMT1

PRMT1

Protein arginine N-methyltransferase 1 · Q99873 · PRMT1 on Sugi Atlas →

58,726 patent compounds predicted against PRMT1, 36,775 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL71573 SCHEMBL71573 0.82 12/20
Indocyanine Green Acid Form Indocyanine Green Acid Form (SCHEMBL23630) 0.71 10/20
Indocyanine Green Acid Form Indocyanine Green Acid Form (SCHEMBL23631) 0.71 10/20
Indocyanine Green Acid Form Indocyanine Green Acid Form (SCHEMBL335877) 0.71 10/20
SCHEMBL72325 SCHEMBL72325 1.00 9/20
SCHEMBL70106 SCHEMBL70106 0.76 9/20
SCHEMBL70211 SCHEMBL70211 0.76 9/20
SCHEMBL70234 SCHEMBL70234 0.70 9/20
SCHEMBL249681 SCHEMBL249681 0.67 9/20
SCHEMBL31570 SCHEMBL31570 0.53 9/20
SCHEMBL276748 SCHEMBL276748 0.51 9/20
SCHEMBL70116 SCHEMBL70116 0.84 8/20
SCHEMBL147099 SCHEMBL147099 0.53 8/20
SCHEMBL128177 SCHEMBL128177 0.50 8/20
SCHEMBL146976 SCHEMBL146976 0.48 8/20
SCHEMBL100951 SCHEMBL100951 0.48 8/20
SCHEMBL254835 SCHEMBL254835 0.43 8/20
SCHEMBL70723 SCHEMBL70723 0.68 7/20
SCHEMBL70111 SCHEMBL70111 0.56 7/20
SCHEMBL128972 SCHEMBL128972 0.47 7/20

Clinical trials — most relevant to PRMT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
L-Arginine Role for Stone Lower Ureter : A Randomized Control Study PHASE4COMPLETED
Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial PHASE3COMPLETED
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) PHASE3RECRUITING
L-Arginine in Pre-Eclampsia PHASE3COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors PHASE1/PHASE2RECRUITING
Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial PHASE2COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
The Effects of NOx and Conjugated Linoleic Acid on Asthmatics PHASE2COMPLETED
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors PHASE1RECRUITING
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD nanUNKNOWN
The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure nanENROLLING_BY_INVITATION
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
Study of the Articular Microbiota in Rheumatoid Arthritis. nanCOMPLETED
HIIT and MICT on Nitric Oxide-mediated Erythrocyte Rheology nanUNKNOWN
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD nanCOMPLETED
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) nanRECRUITING
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment nanUNKNOWN
Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Diabetes nanUNKNOWN
Arginase Inhibition in Type 1 and Type 2 Diabetes Mellitus nanCOMPLETED
Effect of Arginine and Glutamine on Radiation-induced Oral Mucositis: a Trible Blinded Randomized Controlled Clinical Trial nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
DNA Methylation and Perioperative Pain Treatment nanCOMPLETED
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN) nanUNKNOWN
Serum Anti-PCOLCE as Novel Diagnostic Biomarker in Rheumatoid Arthritis With Emphasis on Seronegative Patients. nanNOT_YET_RECRUITING
Fetal Alcohol Spectrum Disorder-Is This a Ciliopathy? nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PRMT1 binder may also engage these)

ProteinNameSimilarity
Q9JIF0 — 1.000 Q9JIF0 →
Q63009 — 1.000 Q63009 →
Q6VRB0 — 1.000 Q6VRB0 →
Q8AV13 — 1.000 Q8AV13 →
Q28F07 — 0.996 Q28F07 →
PRMT8 Protein arginine N-methyltransferase 8 0.995 landscape →
Q6PAK3 — 0.995 Q6PAK3 →
Q5RGQ2 — 0.990 Q5RGQ2 →
Q9U2X0 — 0.983 Q9U2X0 →
Q5ZIB9 — 0.982 Q5ZIB9 →
A2AV36 — 0.980 A2AV36 →
D9IVE5 — 0.980 D9IVE5 →
Q0J2C6 — 0.980 Q0J2C6 →
O82210 — 0.979 O82210 →
Q54EF2 — 0.979 Q54EF2 →
Q6PCI6 — 0.978 Q6PCI6 →
B3DLB3 — 0.977 B3DLB3 →
A6QQV6 — 0.976 A6QQV6 →
A8IEF3 — 0.976 A8IEF3 →
Q9SU94 — 0.976 Q9SU94 →
Q9URX7 — 0.976 Q9URX7 →
PRMT5 Protein arginine N-methyltransferase 5 0.975 landscape →
A2Z0C0 — 0.974 A2Z0C0 →
Q8CIG8 — 0.974 Q8CIG8 →
Q6NUA1 — 0.973 Q6NUA1 →
Q922X9 — 0.973 Q922X9 →
Q5R698 — 0.973 Q5R698 →
A7YW45 — 0.972 A7YW45 →
Q99MI9 — 0.972 Q99MI9 →
Q8N1G2 — 0.972 Q8N1G2 →